News
EYEN
0.6863
-3.51%
-0.0250
12 Health Care Stocks Moving In Thursday's Intraday Session
Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. Akso Health Group ( NASDAQ:AHG) shares increased by 29.87%. Processa Pharma (NASdaq:PCSA) stock increased by 43.18%. Cyclacel Pharmaceuticals stock declined by 33.1% during the session.
Benzinga · 23h ago
Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension
Company announces results from a Phase IV study of Mydcombi. The study was designed to characterize the efficacy and duration of the lowest deliverable dose. Also announces upcoming ARVO presentation on the unique technology behind clobetasol for future ophthalmic suspensions.
Benzinga · 1d ago
Weekly Report: what happened at EYEN last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at EYEN last week (0408-0412)?
Weekly Report · 04/15 11:36
12 Health Care Stocks Moving In Wednesday's Intraday Session
Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 61.6% to $1.83 during Wednesday's regular session. Orgenesis stock rose 27.83% and Jaguar Health shares rose 32.22% during the same period. Telomir Pharmaceuticals and Orgen Genesis were the biggest gainers in the company's stock.
Benzinga · 04/10 16:31
EYENOVIA: OFFERING TO CERTAIN PURCHASERS 3.2 MLN SHARES OF COMMON STOCK, AT A PRICE OF $0.6204 PER SHARE FOR PURCHASE PRICE OF $2 MLN- SEC FILING
Reuters · 04/10 10:09
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
NASDAQ · 04/09 13:29
Eyenovia Shares Fall More Than 14% After Company Says It Is Exploring Sale
Shares of Eyenovia down 14.6% to 76 cents during Monday trading. The company said it was exploring strategic options, including a potential sale. Eyenovo's shares are down 63% year to date. The ophthalmic company also said it would accelerate development of a product for nearsightedness.
Dow Jones · 04/08 18:38
BUZZ-U.S. STOCKS ON THE MOVE-Perpetua Resources, Huntington Bancshares, FuelCell Energy
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,942.47. The top three S&P 500 percentage gainers were Albemarle, Tesla and Tesla. Boeing and Boeing Co were among the biggest decliners.
Reuters · 04/08 18:05
BUZZ-U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,941.91. The top three S&P 500 percentage gainers were Tesla, GE and Ameresco. Treasury yields retreated from session highs as investors awaited the Fed's rate outlook.
Reuters · 04/08 16:11
BUZZ-U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Futures tracking Wall Street's main indexes were largely muted on Monday. Treasury yields rose on rising bets that the U.S. Federal Reserve could delay interest-rate cuts this year. Dow e-minis were up 0.13% in early trading. Ocugen up 9.8% on FDA approval of gene therapy for Parkinson's disease.
Reuters · 04/08 13:50
BUZZ-Eyenovia rises on plans to explore strategic alternatives
Shares of eye drugmaker Eyenovia Inc rise 3.4% to 92 cents premarket. Co says it has started a process to explore strategic alternatives. Plans to develop potential multi-billion dollar product called MicroPine for pediatric progressive myopia. Company expects to file for marketing approval in 2025.
Reuters · 04/08 12:02
Weekly Report: what happened at EYEN last week (0401-0405)?
Weekly Report · 04/08 11:42
Eyenovia Explores Options, Including Potential Sale
Ophthalmic company Eyenovia says it is exploring strategic options, including a potential sale of the company. The New York company sports a market capitalization of about $42 million. The company says it will focus on accelerating development of its myopia products. In addition to a sale, the company will consider a range of options.
Dow Jones · 04/08 11:21
Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia. Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses. The company's two FDA-approved products are MicroPine.
Benzinga · 04/08 11:02
EYENOVIA INC: PLANS TO CONSIDER A WIDE RANGE OF OPTIONS, INCLUDING POTENTIAL SALE OF ASSETS OF CO, A SALE OF CO, ETC
Reuters · 04/08 11:01
UPDATE 2-Lenz Therapeutics' eye drop helps improve vision in late-stage study
Lenz Therapeutics' eye drop helps improve vision in late-stage study. Shares of the company gained as much as 17% earlier in the day. The once-daily eye drop is being tested to treat presbyopia, a common age-related eye disorder. The company plans to submit a U.S. Marketing application for the drug.
Reuters · 04/03 11:27
Tuesday 4/2 Insider Buying Report: EYEN, GTN
NASDAQ · 04/02 17:41
Weekly Report: what happened at EYEN last week (0325-0329)?
Weekly Report · 04/01 11:38
Weekly Report: what happened at EYEN last week (0318-0322)?
Weekly Report · 03/25 11:42
More
Webull provides a variety of real-time EYEN stock news. You can receive the latest news about Eyenovia Inc through multiple platforms. This information may help you make smarter investment decisions.
About EYEN
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.